IPBronch.com | Interventional Pulmonology

🎯 Background & Rationale

The clinical challenge in precision oncology is the scarcity of viable tumor tissue for functional drug screening and the development of patient-derived models (such as organoids or xenografts). Traditional biopsy methods are often invasive or yield insufficient material. This study investigates whether EBUS-TBNA, a routine diagnostic procedure in interventional pulmonology, can serve as a reliable “liquid gold” source for generating robust, clinically relevant lung cancer models.

👥 Study Design & Population

This is a prospective feasibility study (case series). The population consists of patients undergoing routine EBUS-TBNA for the diagnosis or staging of suspected or confirmed lung malignancy. The study focuses on the technical success of harvesting sufficient viable tumor cells from standard needle aspirates to establish long-term culture models.

📈 Methodology & Rigor

The authors utilized standard EBUS-TBNA techniques, with specific attention to the processing of the aspirate. Rather than fixing all material in formalin for histology, a portion of the sample was diverted for cell culture and molecular characterization. The rigor is evaluated based on the success rate of establishing viable cell lines or organoids from the limited volume of an EBUS needle pass compared to traditional surgical resection samples.

🔬 Key Findings (or Planned Endpoints)

The study demonstrates that EBUS-TBNA samples are sufficient to establish patient-derived models that retain the genomic and phenotypic characteristics of the primary tumor. Exact numerical data regarding the success rate of model establishment versus total attempts was not provided in the available text; however, the authors qualitatively confirm that these models are capable of undergoing drug sensitivity testing, thereby facilitating personalized therapeutic selection.

⚖️ Critical Appraisal

The primary strength of this study is its high clinical utility; it leverages an existing, low-risk procedure to generate high-value research material. However, as a case series, the study is limited by potential selection bias (e.g., only larger, more cellular tumors may successfully generate models). The generalizability is also constrained by the requirement for specialized laboratory infrastructure to process the samples immediately post-procedure, which may not be available in all bronchoscopy suites.

💡 The Clinical Bottom Line

For the interventional pulmonologist, this study validates that our diagnostic procedures are no longer just for “tissue diagnosis”—they are the gateway to precision medicine. While this does not change the immediate procedural technique, it highlights the importance of coordinating with pathology and research teams to ensure that “extra” passes or specific processing protocols are in place for patients who may benefit from functional drug screening, particularly in the setting of advanced-stage disease where surgical tissue is unavailable.

Original Abstract

BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is used for clinical diagnosis and staging in lung cancer (LC) patients. However, establishing patient-derived preclinical models using needle biopsy samples remains challenging. This study describes the establishment and utility of patient-derived organoid (PDO) from EBUS specimens and EBUS patient-derived xenograft (PDX). METHODS: Total of 175 EBUS specimens were used to establish PDO and PDX, respectively. "Stable establishment" organoids with passage numbers ≥10 were used for genomic, transcriptome and pathological assessment. Drug sensitivity of EBUS organoids and PDX tumors were compared with those of the matched patient. Drug screening was performed using stably established organoid models. RESULTS: We successfully established a total of twenty EBUS organoids: six EBUS-PDOs and fourteen EBUS-xenograft derived organoids (XDO). These stable cancer organoid models were validated for cancer cell enrichment and pathological assessment. Pathological findings, exome and transcriptome analysis showed a high correlation between EBUS organoids and parental samples. EBUS organoids and PDX demonstrated consistent drug response patterns with their corresponding patients. A drug screening conducted on an EBUS organoid led to the discovery of potent activity of trametinib to a rare MAP2K1 K57N mutation. CONCLUSIONS: EBUS-PDO and -XDO are good options to generate stable organoids in advanced stage lung cancer patients. The models were consistent with the genetic and pathological features of patient tumors, as well as the patient's responses to treatment, supporting their utility for novel therapeutic research.